Combination 5-azacytidine and nivolumab for squamous cell carcinoma of head and neck

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 7 Apr 2022: Trial registered, NCT05317000
  2. 23 Mar 2023: Trial started, NCT05317000

The trials

NCT05317000: 5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC

State
Under way
Phase
Phase 2
People
50 planned
Started
23 Mar 2023
Primary completion
30 Jun 2028
Arms
Arm C: Combination 5-azacytidine and Nivolumab
Results
None posted
  1. 7 Apr 2022: Trial registered
  2. 23 Mar 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.